VWK-54661-42702
3 vaccinations
1 coded response
12 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 212 / MD
- Registered
- 2021-09-30
- Relationship
- Self
- Race
- White
- Ethnicity
- N/A
Registered dependents
QA6-18398-12397
Child or adolescent in my care · Male · 2022-06-25
WM9-25747-51983
Child or adolescent in my care · Female · 2022-06-25
Timeline
-
2021-01-20
Dose 1 — Pfizer-BioNTech
-
2021-02-15
Dose 2 — Pfizer-BioNTech
-
2021-09-30
Registered in v-safe
-
2021-10-29
Dose 3 — Pfizer-BioNTech
-
2021-11-01
Health check-in — days 1–6 daily, dose 3Feeling: Good · Site: Pain, Redness, Swelling · NoneAdult check-in
- 2021-11-02
- 2021-11-03
- 2021-11-04
- 2021-11-05
- 2021-11-12
- 2021-11-19
- 2021-11-28
- 2021-12-03
- 2021-12-10
-
2022-01-28
Survey response — 3 months, dose 3MedDRA: Chest discomfort, Oropharyngeal pain, Rhinorrhoea — Feeling: GoodFree text: Sore throat, runny nose, chest pressureMedDRA releases: 2024-11 · check-in free text available
- 2022-05-01
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-20 | Pfizer-BioNTech | No |
| 2 | 2021-02-15 | Pfizer-BioNTech | No |
| 3 | 2021-10-29 | Pfizer-BioNTech | No |
Free text
Release 11 — 3 months, dose 3
Symptoms: Sore throat, runny nose, chest pressure
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Chest discomfort | · | · | ✓ |
| SD | Oropharyngeal pain | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release